Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the European Medicines Agency:
TAGRISSO as a monotherapy is indicated for the treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.